Evidence map›Paper›PMID 38696707›Full record

SynthesisBlood advances2024

The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review.

Ramya Ramachandran, Darshi Shah, Catherine Luo, Veer Shah, Edward R Scheffer Cliff, Vaishali Sanchorawala, Suzanne Lentzsch, Rajshekhar Chakraborty

Abstract readLetterSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ramya RamachandranMedical City Healthcare, Hospital Corporation of America, Arlington, TX.ORCID 0000-0003-2681-163X
Darshi ShahRenaissance School of Medicine at Stony Brook University, Stony Brook, NY.ORCID 0009-0002-6784-0058
Catherine LuoRenaissance School of Medicine at Stony Brook University, Stony Brook, NY.ORCID 0000-0002-2646-9566
Veer ShahDepartment of Mechanical and Industrial Engineering, Northeastern University, Boston, MA.ORCID 0000-0002-6337-9455
Edward R Scheffer CliffProgram on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0001-5977-907X
Vaishali SanchorawalaDepartment of Medicine, Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA.ORCID 0000-0002-6307-2445
Suzanne LentzschDepartment of Medicine, Multiple Myeloma and Amyloidosis Program, Columbia University Irving Medical Center, New York, NY.
Rajshekhar ChakrabortyDepartment of Medicine, Multiple Myeloma and Amyloidosis Program, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-7336-3003

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Clinical Trials as TopicImmunoglobulin Light-chain AmyloidosisHumansImmunoglobulin Light ChainsImmunoglobulin Light Chains

Identifiers

PMID38696707
PMCPMC11260830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.